Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Pulmonary Embolism Thrombolysis a Double-Edged Sword

By HospiMedica International staff writers
Posted on 30 Jun 2014
A new study has found that thrombolytic therapy (TT) nearly halved mortality in patients with pulmonary embolism (PE), but at the cost of a higher risk of major bleeding.

Researchers at St. More...
Luke's-Roosevelt Hospital Center (New York, NY, USA), Thomas Jefferson University Hospital (Philadelphia, PA, USA), and other institutions conducted a meta-analysis of studies to determine mortality benefits and bleeding risks associated with TT compared with anticoagulation in acute PE. In all, 16 eligible trials comprising 2,115 individuals were identified over the past four decades. The primary outcomes were all-cause mortality and major bleeding; secondary outcomes were risk of recurrent embolism and intracranial hemorrhage (ICH).

The results showed that TT was associated with a 47% reduction in mortality, and a 2.7-fold increase in major bleeding compared with standard anticoagulant therapy. Major bleeding was not significantly increased in patients younger than age 65, but a subgroup analysis of patients over the age of 65 revealed a threefold increase in risk of major bleeding. Only one small study evaluated the use of catheter-directed TT, which limited the study’s generalizability beyond patients receiving systemic treatment. The study was published in the June 18, 2014, issue of the Journal of the American Medical Association (JAMA).

“Among patients with pulmonary embolism, including those who were hemodynamically stable with right ventricular dysfunction, thrombolytic therapy was associated with lower rates of all-cause mortality and increased risks of major bleeding and ICH,” concluded lead author Saurav Chatterjee, MD, of St. Luke's-Roosevelt, and colleagues. “However, findings may not apply to patients with pulmonary embolism who are hemodynamically stable without right ventricular dysfunction.”

PE is most often caused by a blood clot migrating to the lungs, with the most common source being a deep vein thrombosis (DVT); less common causes include air bubbles, fat droplets, amniotic fluid, or clumps of parasites or tumor cells. Risk factors include burns, cancer, childbirth, a family history of blood clots, fractures of the hips or thigh bone, heart attack or heart surgery, long-term bed rest, severe injury, stroke, surgery, use of birth control pills or estrogen therapy.

Related Links:

St. Luke's-Roosevelt Hospital Center
Thomas Jefferson University Hospital



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.